455 — Tianda Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- HK$580.51m
- HK$502.57m
- HK$509.96m
- 21
- 33
- 46
- 20
2018 March 31st | 2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 362 | 527 | 491 | 474 | 510 |
Cost of Revenue | |||||
Gross Profit | 270 | 424 | 361 | 259 | 241 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 332 | 501 | 475 | 501 | 537 |
Operating Profit | 29.9 | 26.2 | 16.3 | -26.9 | -27.3 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 29.9 | 26.2 | 15.9 | -27.4 | -28 |
Provision for Income Taxes | |||||
Net Income After Taxes | 22.2 | 16 | 8.8 | -25.9 | -21.7 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 10 | 2.66 | 3.14 | -27.1 | -19.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 10 | 2.66 | 3.14 | -27.1 | -19.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.005 | 0.001 | 0.002 | -0.013 | -0.012 |
Dividends per Share | |||||
Special Dividends per Share |